Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector newsTweets 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24/2012 | 07:59am CEST

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
06/23 DAIICHI SANKYO : ProLynx collaborates with Daiichi Sankyo on drug delivery
06/22 OSCAR INVESTMENTS : High court tells former ranbaxy promoters to maintain value ..
06/20 DAIICHI SANKYO : ProLynx announces collaboration with Daiichi Sankyo to evaluate..
06/09 DAIICHI SANKYO : New Findings on Inflammation Mediators Described by Investigato..
06/09 DAIICHI SANKYO : Studies from Daiichi Sankyo Have Provided New Data on Medicinal..
06/09 DAIICHI SANKYO : and Inspirion Delivery Sciences LLC Announce Plans for Commerci..
06/01 DAIICHI SANKYO : Cancer Enterprise Pipeline Data Showing Swift Progress in Preci..
05/18 DAIICHI SANKYO : Data on Carboxylic Ester Hydrolases Reported by Researchers at ..
05/11 DAIICHI SANKYO : Researchers at Daiichi Sankyo Report New Data on Toxicology (Co..
More news
Sector news : Pharmaceuticals - NEC
09:22a COVESTRO : vows to cash out to shareholders if no takeover on cards
04:55a MYLAN : Investors call on Mylan chairman, director to step down
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/13 FDA's Gottlieb taking aim at opioid epidemic, wants post-market studies to co..
06/09 KemPharm on deck to present data on hydromorphone prodrug KP511
05/30 Daiichi Sankyo to lead U.S. commercialization of Inspirion's abuse-deterrent ..
05/11 Daiichi Sankyo reports FY results
05/10 Pieris Blooms With Astra Deal
Financials ( JPY)
Sales 2018 918 495 M
EBIT 2018 -
Net income 2018 67 936 M
Finance 2018 360 487 M
Yield 2018 2,75%
P/E ratio 2018 24,97
P/E ratio 2019 27,36
EV / Sales 2018 1,57x
EV / Sales 2019 1,69x
Capitalization 1 801 598 M
More Financials
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 12
Average target price 2 570  JPY
Spread / Average Target 1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON17.19%360 489
ROCHE HOLDING LTD.8.34%226 454
NOVARTIS11.74%223 476
PFIZER3.91%200 985
MERCK AND COMPANY10.68%178 223
More Results